Teva Pharmaceutical Industries (NYSE:TEVA) on Tuesday said it has upsized its offering and priced about $2.3B of its senior notes.
The principal amount of the offering was increased from the offering size of $2B.
The notes consist of Teva Pharmaceutical Finance Netherlands II B.V’s €1B aggregate principal amount of 4.125% EUR-denominated Senior Notes maturing in 2031, Teva Pharmaceutical Finance Netherlands III B.V.’s $500M aggregate principal amount of 6.000% USD-denominated Senior Notes maturing in 2032 and Teva Pharmaceutical Finance Netherlands IV B.V.’s $700M aggregate principal amount of 5.750% USD-denominated Senior Notes maturing in 2030.
The settlement of the Notes is expected to occur on or about May 28, 2025.
